Our Pricing

Mounjaro vs Wegovy Weight Loss: Complete Dose Range

Published on: June 03, 2026

Choosing between Mounjaro vs Wegovy weight loss UK treatments requires understanding how tirzepatide and semaglutide differ in mechanism, efficacy, and dosing schedules. Both are MHRA-licensed weekly injections that have transformed weight management outcomes in clinical trials, but they work through distinct pathways and produce different results. Our UK-registered clinical team can help you determine which treatment aligns with your weight loss goals during a free online consultation.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for weight management [1]. This dual mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, regulating appetite, slowing gastric emptying, and improving insulin sensitivity through two complementary pathways.

Wegovy contains semaglutide, a single GLP-1 receptor agonist that mimics the natural GLP-1 hormone to reduce hunger and increase feelings of fullness [2]. While semaglutide has demonstrated substantial weight loss in clinical trials, tirzepatide's dual-receptor activity has shown superior results in head-to-head comparisons, with patients achieving greater average weight reduction over comparable treatment periods [1][3].

Both medications require once-weekly subcutaneous injection and are prescription-only treatments in the UK, requiring clinical assessment by a registered prescriber before dispensing.

Clinical Trial Results: Mounjaro vs Wegovy Weight Loss Outcomes

In the SURMOUNT-1 trial, patients taking the highest Mounjaro dose (15mg) achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. Nearly 40% of participants on the 15mg dose lost at least 25% of their initial body weight, representing outcomes previously associated only with bariatric surgery.

The STEP 1 trial demonstrated that Wegovy 2.4mg produced an average weight loss of 14.9% over 68 weeks, with 32% of participants achieving at least 20% weight reduction [2]. While these results represent significant clinical benefit, the magnitude of weight loss was notably lower than tirzepatide outcomes in comparable patient populations.

A 2023 indirect comparison published in Obesity Reviews found that tirzepatide 10mg and 15mg doses produced statistically greater weight reduction than semaglutide 2.4mg across multiple endpoints, though both treatments demonstrated substantially better outcomes than lifestyle modification alone [3].

Real-World Effectiveness

Clinical trial results represent controlled conditions with high adherence rates and regular monitoring. Real-world effectiveness depends on consistent weekly dosing, dietary modifications, and physical activity levels. Our UK prescribers provide ongoing support to help you maintain treatment adherence and optimise your weight loss journey, regardless of which medication you're prescribed.

Complete Dose Ranges and Titration Schedules

Mounjaro follows a gradual dose escalation schedule starting at 2.5mg weekly for four weeks, then increasing to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg based on individual tolerance and response [4]. This titration approach minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's metabolic effects.

Wegovy begins at 0.25mg weekly, doubling approximately every four weeks through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg weekly [5]. The slower initial titration with Wegovy reflects semaglutide's potent GLP-1 activity and helps reduce nausea and vomiting during the adaptation period.

Your UK prescriber will determine your starting dose and escalation schedule based on your medical history, current medications, weight loss goals, and tolerance during treatment. Some patients may remain on lower maintenance doses if they achieve satisfactory weight loss with minimal side effects, whilst others may require maximum doses for optimal results.

Adjusting Your Dose

Dose adjustments should only be made under prescriber supervision. If you experience persistent gastrointestinal symptoms, your prescriber may slow the titration schedule or maintain you at your current dose for additional weeks before escalating. Never adjust your dose independently or skip the titration schedule, as this significantly increases the risk of adverse effects.

Side Effects: What to Expect with Each Treatment

Both medications share a common side effect profile dominated by gastrointestinal symptoms including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects typically peak during dose escalation periods and diminish as your body adapts to the medication over several weeks.

In SURMOUNT-1, approximately 6% of Mounjaro patients discontinued treatment due to adverse effects, most commonly gastrointestinal symptoms [1]. Wegovy showed similar discontinuation rates of 7% in STEP 1, with nausea being the most frequently reported reason for stopping treatment [2].

Serious but rare side effects include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). Both medications carry boxed warnings about thyroid tumour risk and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4][5].

Your UK prescriber will review your complete medical history during consultation to identify any contraindications or conditions requiring additional monitoring whilst taking these medications.

Cost Comparison and UK Availability

At Cured Pharmacy, Mounjaro is available from £124.99 per pen, with pricing varying based on your prescribed dose strength. Wegovy starts at a lower price point, making it a more accessible option for some patients, though total treatment costs depend on your maintenance dose and treatment duration.

Both medications have experienced intermittent supply constraints across UK pharmacies due to unprecedented demand. Cured Pharmacy maintains strong relationships with licensed wholesalers to ensure consistent stock availability, and our transparent pricing means you'll know the exact cost before completing your clinical assessment.

Unlike some providers, we display upfront pricing for all dose strengths before you begin your consultation, allowing you to make informed decisions about which treatment fits your budget. All prices include UK prescriber assessment, medication dispensing, and discreet delivery to your preferred address.

Insurance and NHS Availability

NHS prescribing of weight loss medications is currently restricted to specialist services and specific eligibility criteria including BMI thresholds and comorbid conditions. Most UK patients access Mounjaro and Wegovy through private prescriptions from registered online pharmacies like Cured Pharmacy, where clinical assessment and dispensing can be completed within days rather than months.

Which Treatment Is Right for You?

Choosing between Mounjaro and Wegovy depends on your weight loss goals, medical history, tolerance for potential side effects, and budget considerations. Patients seeking maximum weight reduction based on clinical trial data may prefer Mounjaro's dual-receptor mechanism, whilst those prioritising lower initial costs or who have successfully used GLP-1 medications previously may opt for Wegovy.

Your UK prescriber will assess your BMI, existing medical conditions, current medications, previous weight loss attempts, and personal preferences during your online consultation. Factors such as diabetes status, cardiovascular risk, and gastrointestinal sensitivity all influence treatment selection and dosing strategies.

Both medications require commitment to dietary modifications and increased physical activity for optimal results. Clinical trials demonstrating significant weight loss included lifestyle counselling and calorie restriction alongside medication, highlighting that these treatments work best as part of a comprehensive weight management programme rather than standalone solutions.

Start your free online consultation at Cured Pharmacy to discuss whether Mounjaro or Wegovy aligns with your weight loss objectives. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides personalised treatment recommendations based on current NICE and MHRA guidance.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Chavda, V. P., Ajabiya, J., Teli, D., et al. (2023). Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 27(13), 4315. https://doi.org/10.3390/molecules27134315 [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/14298 [accessed 13 August 2026]
5. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and physical activity levels.